CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Phase 1
- Conditions
- Refractory B Cell Acute Lymphoblastic Leukemia (ALL)Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Biological: CD19 CAR engineered autologous T-cells
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Sabz Biomedicals
- Target Recruit Count
- 22
- Registration Number
- NCT04653493
- Locations
- 🇮🇷
Gene therapy research center, Shariati hospital, Tehran university of medical sciences, Iran, Tehran, Iran, Islamic Republic of
🇮🇷Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
Autologous Killer Cell Therapy in Colon Cancer Patients
Phase 1
- Conditions
- Colon Cancer Stage IV
- Interventions
- Biological: Cytokine-induced killer cellOther: Chemotherapy AND/OR Radiation Therapy
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Sabz Biomedicals
- Target Recruit Count
- 20
- Registration Number
- NCT03329664
- Locations
- 🇮🇷
Gene Therapy Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
© Copyright 2025. All Rights Reserved by MedPath